Ivan Kairatov stands at the forefront of the biopharmaceutical evolution, where traditional
The treatment landscape for pancreatic ductal adenocarcinoma has long been characterized by a
The quest to recreate the intricate complexity of human tissue within a laboratory setting has long been hindered by the limitations of static synthetic materials that fail to communicate with living cells. As bioengineering transitions from simple scaffolds to dynamic, interactive systems,
The intersection of computational intelligence and molecular biology has revealed a shocking source for the next generation of life-saving medicine: the same infectious proteins responsible for devastating neurological disorders like Creutzfeldt-Jakob disease. Researchers at the Perelman School of
The race to treat Alzheimer’s has entered a new era with the approval of monoclonal antibody
The longstanding biological assumption that the genetic blueprint for chronic metabolic diseases
Advanced Therapy Medicinal Products cannot be scaled the same way biologics were. The core constraint is not steel and glass. It is biology, variability, and a regulatory environment that requires…
The biopharma playbook is being actively rewritten. After years of chasing breakthrough science at
In 2026, boards and customers are asking a direct question: can promising science be turned into
The pharmaceutical sector is entering a decisive phase as obesity therapeutics gain more ground as
The End of the Old Biopharma Playbook The biopharmaceutical industry is confronting a structural
The landscape of modern telemedicine is undergoing a fundamental transformation as established players move beyond simple video consultations to become fully integrated, technology-driven health platforms. Hims & Hers Health exemplifies this shift, reporting a second quarter that highlights the
The global landscape of humanitarian assistance is currently witnessing a profound and
The rapid proliferation of foundation models has fundamentally altered the trajectory of medical
